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IntroductIon
Central venous occlusive disease (CVOD) is a com-
mon and growing problem in the long-term management 
of vascular access patency in patients undergoing haemo-
dialysis. Additionally, the number of dialysis patients is 
also increasing, and up to 50% of them will experience 
CVOD after haemodialysis catheter use [1]. However, 
more than half of them may experience symptomatic res-
olution after removal of the dialysis catheter, obviating 
the need for invasive treatment [2]. Following catheter 
removal, 28% of all patients have radiological evidence 
of central vein stenosis (CVS) persisting beyond three 
months [3]. In symptomatically refractory cases, inter-
vention is required. Percutaneous transluminal angio-
plasty (PTA), occasionally accompanied by stenting 
(PTS), is accepted as the initial intervention for patients 
with CVOD [4].
The objective of our report was to evaluate the results 
of endovascular CVOD treatment in patients with hae-
modialysis shunts.
MaterIal and Methods
Eighty-one consecutive patients with CVOD referred 
for treatment in our tertiary interventional centre were 
included into the study group.
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abstract
Objectives: The objective of our report was to present the results of two-year fol-
low-up of endovascular treatment of central venous occlusive disease in haemodial-
ysis patients.
Material and methods: Eighty-one consecutive patients with central venous occlusive 
disease, were included into the study group. There were 81 lesions treated (42 stenosis 
and 39 occlusions). Percutaneous transluminal angioplasty (PTA) or percutaneous 
transluminal angioplasty with stenting (PTS) was committed. There was no randomi-
sation. Stent implantation was avoided in vessels with a foreign body inside (catheter 
or electrode). Diagnostic phlebographies were performed after 12 and 24 months or if 
symptoms recurred. The follow-up period lasted for 24 months. There were 26 (70%) 
patients with primary stenosis and 11 (29%) with occlusion in the group with PTA 
therapy and 13 (38%) and 21 (61%) in the group with PTS therapy. Procedure was 
successful in all cases of stenosis, unsuccessful in 10 cases of occlusions. Seventeen 
patients died during first year of observation, 9 during the second. Two patients were 
lost to follow up. No serious adverse events were observed.
Results: Primary patency (PP) after 12 and 24 months was 50% and 26% after PTS, 
33% and 21% after PTA respectively. Primary assisted patency (PAP) was 70% and 
52% in PTS group while 86% and 92% in PTA group. Secondary patency (SP) 70% 
and 52% after PTS to 93% and 92% after PTA.
Conclusions: Both methods are safe and mildly effective in the treatment of central 
veins in haemodialysis patients. Both techniques should be applicable in specific clin-
ical settings according to patient status and operator experience.
Key words: haemodialysis, stenting, balloon angioplasty, endovascular treatment, 
central vein.
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The inclusion criteria were: 1) clinically significant 
shunt dysfunction and/or 2) limb oedema. Lesions were 
characterised at baseline by the type (stenosis versus 
occlusion), location, segmental length, and diameter of 
stenosis (where applicable). Patients were treated with 
PTA or PTS whenever essential. There was no randomi-
sation, and the decision for stent implantation (i.e. PTS) 
was based on two criteria: 1) residual, post-angioplasty 
stenosis ≥ 60% and/or 2) persistent collaterals. The fol-
low-up period lasted for 24 months. The results of fol-
low-up phlebography performed at 12 and 24 months 
after endovascular treatment were categorised as: steno-
sis < 50%, stenosis > 50%, or occlusion. The results were 
then compared according to the method of treatment: 
PTA versus PTS. The outcomes were: primary, primary 
assisted, and secondary patency rates, respectively. The 
primary patency (PP) was defined as the vessel patency 
without any re-intervention, secondary patency (SP) as 
the vessel patency achieved with additional intervention 
or multiple interventions due to vessel occlusion, while 
primary assisted patency (PAP) was defined as patency 
achieved with additional intervention or multiple inter-
ventions due to vessel restenosis [5]. The data were ana-
lysed retrospectively.
SPSS package (SPSS Inc. Released 2009. PASW 
Statistics for Windows, Version 18.0. Chicago: SPSS 
Inc.) was used to evaluate variables in descriptive sta-
tistics and Fisher’s exact test. Data were also analysed in 
respective contingency tables. Barnard’s exact test was 
also used to assess statistical differences using R exact 
package (Calhoun P [2015]. Unconditional Exact Test. 
R package version 1.6).
results
A total of 81 haemodialysis patients (47 males and 
34 females; mean age: 64.5 ±13.0 years) with stenotic 
or occlusive lesions were treated in our study (Table 1). 
There were 81 lesions treated (42 stenosis and 39 occlu-
sions). There were 26 (70%) patients with primary steno-
sis and 11 (29%) with occlusion in the group with PTA 
therapy and 13 (38%) with stenosis and 21 (61%) in the 
group with PTS therapy. The procedure was successful 
in all cases of stenosis but unsuccessful in 10 cases in 
occlusion group. Those 10 casews were excluded from 
further follow up. Seventeen patients died (cause not 
related to procedure) during the first year of observation, 
and nine during the second year. Two patients were lost 
to follow-up. No serious adverse events were observed.
The mean initial lesion stenosis was 86.5% (range: 
60-95%) with segmental lesion length of 25.3 mm in the 
PTA group, and 82% (range: 65-95%) with 28.3 mm-le-
sion lenght in the PTS group, respectively. No signifi-
cant differences regarding the location of lesions in the 
patients’ body side were found between the two groups.
The results of diagnostic phlebographies are shown 
in Table 2.
The differences in the number of occluded vessels on 
the left and right sides of the body were also observed. 
Venous occlusions appeared to be more frequent on the 
right side of the body at 12 months (Table 3). No serious 
adverse events such as death, myocardial infarction (MI), 
stroke, or serious bleeding caused by vessel rupture were 
observed. No stent migration, stent fracture, or signifi-
table 1. Patients’ characteristics
patient characteristic number of patients,  
n (total = 81)
Male 47
Mean age ±SD (years) 64.2 ±13.1
Coronary heart disease (CHD) 41
Peripheral artery occlusive disease (PAOD) 9
Hypertension (HTN) 59
Congestive heart failure (CHF) 12
Stroke/transient ischemic attack (TIA) 9
Diabetes mellitus (DM) 31
Smoking 17
Chronic obstructive pulmonary disease (COPD) 5
table 2. Results of diagnostic phlebographies at 12 and 24 
months
stenotic group (stg) occlusive group (ocg)
 12-month result                                                        total = 54
                                                  n = 31                        n = 23
Stenosis < 50% [n (%)] 24 (77.4%) 10 (43.4%)
Occlusion [n (%)] 1 (3.22%) 8 (34.7%)
Stenosis > 50% [n (%)] 6 (19.3%) 5 (21.7%)
24-month result                                                          total = 43
                                                  n = 24                         n = 19
Stenosis < 50% [n (%)] 16 (66.6%) 7 (36.8%)
Occlusion [n (%)] 2 (8.3%) 9 (47.3%)
Stenosis > 50% [n (%)] 6 (25%) 3 (15.7%)
table 3. Lesion location
location of lesion(s) number of interventions, n (total = 81)
Right-side 40 (31.5%)
Left-side 37 (29.9%)
Superior vena cava (SCV) 3 (2.4%)
SVC and right-side 2 (1.62%)
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cant stent shortening immediately, or several weeks or 
months after the insertion, were seen.
During the first 12 months of follow-up, a total of 
35 re-interventions were performed, and in the period 
between 12 and 24 months there were 17 (Table 4).
The results of patency rates at both 12 and 24 months 
demonstrated a higher PP rate in the PTS group (50% 
and 26%) than in the PTA group (33% to 21%). Primary 
assisted patency (PAP) rates presented a prevalence in 
the PTA group of 86% and 92% to 70% and 52%, in the 
PTS group. Secondary patency also showed higher rates 
in the PTA group 93% and 92% to 70% and 52% in PTS 
group (Table 5).
dIscussIon
Endovascular treatment is currently the mainstay 
of care in patients with CVOD. The treatment options 
include PTA, PTS, and placement of covered stents. 
Before the development of endovascular techniques, 
open surgical treatment was the only management strat-
egy. Although surgical treatment of CVS is effective (PP 
rate of 80-85% at 1 year) [6], it has significant limita-
tions due to high surgical morbidity (especially among 
patients with stenosis in the thoracic region) and overall 
poor general condition of haemodialysis patients [7]. On 
the contrary, the endovascular technique is a less invasive 
table 4. Number of reinterventions at 12 and 24 months
number of reinterventions
after pta after pts
observation period 0-12  months 12-24  months 0-12 months 12-24 months
Stenotic group (StG) 17 8 2 1
Occlusive group (OcG) 7 2 9 5
PTA – percutaneous transluminal angioplasty; PTS – percutaneous transluminal angioplasty with stenting
table 5. Patency results at 12 and 24 months
 pta group pts group










33.0 21.0 50.0 26.0
Secondary patency 
(SP) rate (%)




86.0 92.0 70.0 52.00
PTA – percutaneous transluminal angioplasty; PTS – percutaneous transluminal 
angioplasty with stenting
treatment modality for CVS. Questions arise, however, 
concerning the durability and efficacy of angioplasty in 
the treatment of CVS. There are numerous studies that 
apply different methods of endovascular CVOD treat-
ment [8-10]. However, most of them are small, uncon-
trolled, single institution studies. As such, the data 
reported in these studies for angioplasty alone are usually 
not sufficient to merit recommendation. The PP rates for 
PTA are reportedly between 28% [11] and 55% [9] at six 
months and between 9% [12] and 29% [10] at 12 months. 
Percutaneous transluminal angioplasty is associated with 
a better success rate than PTA, but there is a lack of reli-
able randomised trials. Additionally, stents may break, 
migrate, or shorten during deployment. Stent placement 
may also preclude future endovascular procedures or sur-
gical revisions and could incite intimal hyperplasia lead-
ing to recurrent stenosis and multiple re-interventions. 
The PP rates for PTS technique range from 33% [13] to 
68% [14] at six months and from 19% [13] to 21% [10] 
at 12 months.
Our study presents data that are consistent with 
numerous previous reports on the subject, thus demon-
strating the safety and efficacy of endovascular tech-
niques in CVOD [10, 15].
Percutaneous transluminal angioplasty technique was 
used in more difficult and more demanding cases (mainly 
venous occlusions) and mostly when a satisfactory result 
was not achieved with PTA alone, rarely as a first choice 
treatment. In our study there was no randomisation or 
matched control group. Thus it is not possible (nor was it 
our intention) to compare directly those methods.
conclusIons
Our 24-month observation indicates that both PTA 
and PTS are safe methods of treatment for central 
vein stenosis and occlusions. Both provide moderate-
ly good results in relation to vessel patency, as well 
as with multiple additional interventions. Especially 
high rates of restenosis and re-occlusions during first 
year of observation lead to the conclusion that patients 
after treatment should be controlled more frequent in 
that period (phlebography, for example, at 3, 6, and 12 
months after the procedure).
49
Endovascular treatment of iatrogenic central vein stenosis and occlusion in patients undergoing haemodialysis – a two-year follow-up
Phlebological Review 2016
The authors declare no conflict of interest.
references
1. Agarwal A.K., Patel B.M., Haddad N.J. Central vein stenosis: 
a nephrologist’s perspective. Semin Dial 2007; 20: 53-62.
2. Rice T.W., Rodriguez R.M., Light R.W. The superior vena cava 
syndrome: clinical characteristics and evolving etiology. Medi-
cine (Baltimore) 2006; 85: 37-42.
3. Hernández D., Díaz F., Rufino M., Lorenzo V., Pérez T., 
Rodríguez A., De Bonis E., Losada M., González-Posada J.M., 
Torres A. Subclavian vascular access stenosis in dialysis patients: 
natural history and risk factors. J Am Soc Nephrol 1998; 9: 
1507-1510.
4. Vascular Access Work Group. Clinical practice guidelines for 
vascular access. Am J Kidney Dis 2006; 48 Suppl 1: S248-S273.
5. Zeller T. Current state of endovascular treatment of femo-
ro-popliteal artery disease. Vasc Med 2007; 12: 223-234.
6. Bhatia D.S., Money S.R., Ochsner J.L., Crockett D.E., Chatman 
D., Dharamsey S.A., Mulingtapang R.F., Shaw D., Ramee S.R. 
Comparison of surgical bypass and percutaneous balloon dila-
tation with primary stent placement in the treatment of central 
venous obstruction in the dialysis patients: One-year follow-up. 
Ann Vasc Surg 1996; 10: 452-455.
7. Kundu S. Review of central venous disease in hemodialysis 
patients. J Vasc Interv Radiol 2010; 21: 963-968.
8. Sprouse L.R. 2nd, Lesar C.J., Meier G.H. 3rd, Parent F.N., 
Demasi R.J., Gayle R.G., Marcinzyck M.J., Glickman M.H., 
Shah R.M., McEnroe C.S., Fogle M.A., Stokes G.K., Colonna 
J.O. Percutaneous treatment of symptomatic central venous ste-
nosis. J Vasc Surg 2004; 39: 578-582.
9. Surowiec S.M., Fegley A.J., Tanski W.J., Sivamurthy N., Illig 
K.A., Lee D.E., Waldman D.L., Green R.M., Davies M.G. Endo-
vascular management of central venous stenoses in the hemo-
dialysis patient: results of percutaneous therapy. Vasc Endovas-
cular Surg 2004; 38: 349-354.
10. Bakken A.M., Protack C.D., Saad W.E., Lee D.E., Waldman D.L., 
Davies M.G. Long-term outcomes of primary angioplasty and 
primary stenting of central venous stenosis in hemodialysis 
patients. J Vasc Surg 2007; 45: 776-783.
11. Beathard G.A. Percutaneous transvenous angioplasty in the 
treatment of vascular access stenosis. Kidney Int 1992; 42: 1390-
1397.
12. Asif A., Salman L., Carrillo R.G., Garisto J.D., Lopera G., Bar-
akat U., Lenz O., Yevzlin A., Agarwal A., Gadalean F., Sachdeva 
B., Vachharajani T.J., Wu S., Maya I.D., Abreo K. Patency rates 
for angioplasty in the treatment of pacemaker-induced cen-
tral venous stenosis in hemodialysis patients: results of a mul-
ti-center study. Semin Dial 2009; 22: 671-676.
13. Maya I.D., Saddekni S., Allon M. Treatment of refractory cen-
tral vein stenosis in hemodialysis patients with stents. Semin 
Dial 2007; 20: 78-82.
14. Chen C.Y., Liang H.L., Pan H.B., Chung H.M., Chen W.L., Fang 
H.C., Lo A., Chen C.K., Lai P.H., Yang C.F. Metallic stenting 
for treatment of central venous obstruction in hemodialysis 
patients. J Chin Med Assoc 2003; 66: 166-172.
15. Quinn S.F., Schuman E.S., Demlow T.A., Standage B.A., Rags-
dale J.W., Green G.S., Sheley R.C. Percutaneous transluminal 
angio-plasty versus endovascular stent placement in the treat-
ment of venous stenoses in patients undergoing hemodialysis: 
Intermediate results. J Vasc Interv Radiol 1995; 6: 851-855.
